BOSTON--(BUSINESS WIRE)--Click to Tweet
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for cramps and spasms associated with severe neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), today reported financial results for the year ended December 31, 2016 and provided an update on its clinical development and corporate activities.
“When we initiate our Phase 2 clinical studies in ALS and CMT later this year, FLX-787 will be amongst the most advanced, novel clinical compounds in development for these conditions,” stated Christoph Westphal, M.D., Ph.D., Chair and CEO of Flex Pharma. “With over $61 million in cash and investments at year end, Flex is well funded through early 2019 to execute upon our value-creating objectives.”
